All In Biotech

NDA 214522 · Cmp Dev LLC

Tadliq

Tadalafil · Oral · Phosphodiesterase 5 Inhibitor

Last checked: Nov 19, 2026Latest source record: Jun 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jun 17, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

259

70 Phase 3, 23 recruiting

FAERS reports

32,516

21,489 serious, 3,167 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 15, 2022.

TADLIQ is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). ( 1.1 ) 1.1 Pulmonary Arterial Hypertension TADLIQ ® is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).

Mechanism: Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Pulmonary arterial hypertension is associated with impaired release of nitric oxide by the vascular endothelium and consequent reduction of cGMP concentrations in the pulmonary vascular smooth muscle. PDE5 is the predominant phosphodiesterase in the pulmonary vasculature. Inhibition of PDE5 by tadalafil increases the concentrations of cGMP resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 17, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • TADLIQ · TADALAFIL 20MG/5ML · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tadalafil" as an intervention, any sponsor and status, largest first.

All 259 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea4,261
  • headache3,819
  • diarrhoea3,154
  • nausea2,569
  • fatigue2,536
  • cough2,047
  • dizziness1,957
  • death1,528
  • off label use1,355
  • vomiting1,330
  • drug ineffective1,276
  • pneumonia1,255

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200424
200513
200615
200737
200826
200943
201081
2011185
2012120
2013165
2014213
2015257
2016431
2017408
2018972
20192,934
20202,680
20212,876
20223,544
20234,261
20244,578
20255,104
20263,549

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tadliq (Tadalafil)

2024 spending

$174K

Beneficiaries

14

71 claims

Per beneficiary

$12,416

$12.22 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$145,609
2024$173,822

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 562 on PubMed

Sponsor: Cmp Dev LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.